Statement of Changes in Beneficial Ownership (4)
February 07 2020 - 5:44PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BEHRENS M KATHLEEN |
2. Issuer Name and Ticker or Trading Symbol
IGM Biosciences, Inc.
[
IGMS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/5/2020 |
(Street)
MOUNTAIN VIEW, CA 94043
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $40.27 | 2/5/2020 | | A | | 10000 | | (1) | 2/5/2030 | Common Stock | 10000 | $0.00 | 10000 | D | |
Explanation of Responses: |
(1) | 1/12 of the shares subject to the option shall vest each month following the Issuer's 2020 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2021 Annual Meeting of Stockholders. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
BEHRENS M KATHLEEN C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD MOUNTAIN VIEW, CA 94043 | X |
|
|
|
Signatures
|
/s/ Misbah Tahir, by power of attorney | | 2/7/2020 |
**Signature of Reporting Person | Date |
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jul 2023 to Jul 2024